Menu
Live News EQUITY M impact

TENX: Guggenheim Raises PT

Guggenheim maintains buy rating on Tenax Therapeutics and raises price target to $40

TENX

Guggenheim Maintains Buy on Tenax Therapeutics, Raises Price Target to $40